source
- Sionna's CF add-on pill fails to improve outcomes in Phase 2 trial with TrikaftaSionna Therapeutics reported that its experimental cystic fibrosis pill, SION-719, did not provide any additional benefit when combined with Vertex Pharmaceuticals' Trikafta in a Phase 2 study. Th…
- FDA rejects ITM-11 radiopharmaceutical over manufacturing flaws, halting rival to Novartis therapyThe U.S. Food and Drug Administration issued a rejection letter for ITM-11, a radiopharmaceutical therapy developed by ITM Isotope Technologies Munich, citing manufacturing problems that prevent ap…